Adjuvant therapy in renal cell carcinoma

Francesco Massari; Vincenzo Di Nunno; Chiara Ciccarese; Jeffrey Graham; Camillo Porta; Francesca Comito; Marta Cubelli; Roberto Iacovelli; Daniel Y.C. Heng

doi:10.1016/j.ctrv.2017.09.004

Adjuvant therapy in renal cell carcinoma

Francesco Massari, Vincenzo Di Nunno, Chiara Ciccarese, Jeffrey Graham, Camillo Porta, Francesca Comito, Marta Cubelli, Roberto Iacovelli, Daniel Y.C. Heng

Research output: Contribution to journal › Review article › peer-review

Abstract

Several drugs have demonstrated clinical activity in metastatic renal cell carcinoma (mRCC). The identification of key metabolic pathways has led to the development of novel targeted therapies which have drastically changed the treatment paradigm of mRCC. Moreover, immune-checkpoint inhibitors have recently shown significant activity in advanced disease. Despite these advancements, the role of adjuvant therapy in localized, non-metastatic RCC remains unclear. The utility of many of these agents in the adjuvant setting is currently being actively explored. In this review, we will summarize the main clinical trials investigating adjuvant therapy in renal cell carcinoma, focusing primarily on immunotherapy and targeted agents.

Original language	English
Pages (from-to)	152-157
Number of pages	6
Journal	Cancer Treatment Reviews
Volume	60
DOIs	https://doi.org/10.1016/j.ctrv.2017.09.004
Publication status	Published - Nov 1 2017

Keywords

Adjuvant treatment
Clear cell renal cell carcinoma
Immunotherapy
Renal cell carcinoma
Tyrosine kinases inhibitors

ASJC Scopus subject areas

Oncology
Radiology Nuclear Medicine and imaging

Access to Document

10.1016/j.ctrv.2017.09.004

Cite this

@article{a7facc0c9b50429ea5133a5ef792ba7a,

title = "Adjuvant therapy in renal cell carcinoma",

abstract = "Several drugs have demonstrated clinical activity in metastatic renal cell carcinoma (mRCC). The identification of key metabolic pathways has led to the development of novel targeted therapies which have drastically changed the treatment paradigm of mRCC. Moreover, immune-checkpoint inhibitors have recently shown significant activity in advanced disease. Despite these advancements, the role of adjuvant therapy in localized, non-metastatic RCC remains unclear. The utility of many of these agents in the adjuvant setting is currently being actively explored. In this review, we will summarize the main clinical trials investigating adjuvant therapy in renal cell carcinoma, focusing primarily on immunotherapy and targeted agents.",

keywords = "Adjuvant treatment, Clear cell renal cell carcinoma, Immunotherapy, Renal cell carcinoma, Tyrosine kinases inhibitors",

author = "Francesco Massari and {Di Nunno}, Vincenzo and Chiara Ciccarese and Jeffrey Graham and Camillo Porta and Francesca Comito and Marta Cubelli and Roberto Iacovelli and Heng, {Daniel Y.C.}",

year = "2017",

month = nov,

day = "1",

doi = "10.1016/j.ctrv.2017.09.004",

language = "English",

volume = "60",

pages = "152--157",

journal = "Cancer Treatment Reviews",

issn = "0305-7372",

publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - Adjuvant therapy in renal cell carcinoma

AU - Massari, Francesco

AU - Di Nunno, Vincenzo

AU - Ciccarese, Chiara

AU - Graham, Jeffrey

AU - Porta, Camillo

AU - Comito, Francesca

AU - Cubelli, Marta

AU - Iacovelli, Roberto

AU - Heng, Daniel Y.C.

PY - 2017/11/1

Y1 - 2017/11/1

N2 - Several drugs have demonstrated clinical activity in metastatic renal cell carcinoma (mRCC). The identification of key metabolic pathways has led to the development of novel targeted therapies which have drastically changed the treatment paradigm of mRCC. Moreover, immune-checkpoint inhibitors have recently shown significant activity in advanced disease. Despite these advancements, the role of adjuvant therapy in localized, non-metastatic RCC remains unclear. The utility of many of these agents in the adjuvant setting is currently being actively explored. In this review, we will summarize the main clinical trials investigating adjuvant therapy in renal cell carcinoma, focusing primarily on immunotherapy and targeted agents.

AB - Several drugs have demonstrated clinical activity in metastatic renal cell carcinoma (mRCC). The identification of key metabolic pathways has led to the development of novel targeted therapies which have drastically changed the treatment paradigm of mRCC. Moreover, immune-checkpoint inhibitors have recently shown significant activity in advanced disease. Despite these advancements, the role of adjuvant therapy in localized, non-metastatic RCC remains unclear. The utility of many of these agents in the adjuvant setting is currently being actively explored. In this review, we will summarize the main clinical trials investigating adjuvant therapy in renal cell carcinoma, focusing primarily on immunotherapy and targeted agents.

KW - Adjuvant treatment

KW - Clear cell renal cell carcinoma

KW - Immunotherapy

KW - Renal cell carcinoma

KW - Tyrosine kinases inhibitors

UR - http://www.scopus.com/inward/record.url?scp=85030761088&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030761088&partnerID=8YFLogxK

U2 - 10.1016/j.ctrv.2017.09.004

DO - 10.1016/j.ctrv.2017.09.004

M3 - Review article

C2 - 28992528

AN - SCOPUS:85030761088

VL - 60

SP - 152

EP - 157

JO - Cancer Treatment Reviews

JF - Cancer Treatment Reviews

SN - 0305-7372

ER -

Adjuvant therapy in renal cell carcinoma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this